U.S. Markets closed

Regeneron to Report Results from CD20xCD3 and BCMAxCD3 Bispecifics and C5 Antibody Programs at ASH Annual meeting

New data is from programs in B-cell non-Hodgkin lymphoma, multiple myeloma and paroxysmal nocturnal hemoglobinuria

TARRYTOWN, N.Y., Nov. 6, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will share new and updated data for two investigational medicines for blood cancers and a third for a rare blood disease at the 2019 American Society of Hematology (ASH) Annual Meeting from December 7-10 in Orlando, FL.

Among the accepted abstracts are the first clinical data for REGN5458 (BCMAxCD3) in relapsed/refractory (R/R) multiple myeloma, as well as updated data for REGN1979 (CD20xCD3) in R/R B-cell non-Hodgkin lymphoma (B-NHL). Beyond oncology, the company will share data on pozelimab, a monoclonal antibody designed to block complement factor C5 and prevent the destruction of red blood cells (hemolysis) that cause the symptoms of paroxysmal nocturnal hemoglobinuria (PNH).

"The ASH presentations highlight Regeneron's growing portfolio in blood cancer and rare diseases, including data from two of our six bispecific antibodies currently in clinical development," said David Weinreich, M.D., Senior Vice President, Head of Global Clinical Development and Co-Head of Global Development at Regeneron. "We will also present data on pozelimab, which we are studying in a Phase 2 program in paroxysmal nocturnal hemoglobinuria."

"We continue to make important progress with REGN1979 and are currently enrolling a potentially registrational Phase 2 trial. At ASH, we plan to share new data with additional patients and longer duration of follow-up, with about 20 patients at effective dose levels for each cohort of follicular lymphoma and diffuse large B-cell lymphoma," said Israel Lowy, M.D., PhD, Senior Vice President and Head of Clinical and Translational Sciences for Oncology at Regeneron. "As part of our expanding bispecific portfolio, we will also present encouraging, early single-agent data on REGN5458, our BCMAxCD3 bispecific for multiple myeloma. Additional investigational bispecific antibodies are expected to enter clinical trials in the coming year."

The abstracts published today reflect older data; presentations with updated data will be shared at ASH as follows:

REGN1979

  • Oral presentation: Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20xAnti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL) (Abstract 762; Rajat Bannerji, M.D., Ph.D.: Monday, December 9, 2:45-4:15 PM ET)
  • Poster presentation: A Phase 2 Study of REGN1979, an Anti-CD20xAnti-CD3 Bispecific Antibody (Ab), in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL) (Abstract 4007, Max S. Topp, M.D.: Monday, December 9, 6:00-8:00 PM ET)

REGN5458

  • Poster presentation: Safety and Preliminary Clinical Activity of REGN5458, an Anti-BCMAxAnti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory (R/R) Multiple Myeloma (Abstract 3176; Dennis Cooper, M.D.: Sunday, December 8, 6:00-8:00 PM ET)

Pozelimab/PNH

  • Oral presentation: A Novel Patient Reported Outcome Instrument Assessing the Symptoms of Paroxysmal Nocturnal Hemoglobinuria (Abstract 385; R Paola Daly: Sunday, December 8, 7:30-9:00 AM ET)
  • Poster presentation: Pozelimab, a Human Antibody Against Complement Factor C5, Demonstrates Robust Inhibition of Alternative Complement Activity Both in Normal Human Serum and in Phase I Normal Healthy Volunteers (Abstract 2278; Kishor Devalaraja-Narashimha, Ph.D., DVM: Sunday, December 8, 6:00-8:00 PM ET)
  • Poster presentation: Epidemiology of PNH and Real-World Treatment Patterns Following Incident PNH Diagnosis in the U.S. (Abstract 3407; Jessica J Jalbert, Ph.D.: Sunday, December 8, 6:00-8:00 PM ET)

About the Regeneron Bispecific Antibody Platform
All of Regeneron's bispecific antibodies are designed to closely resemble natural human antibodies. They are derived from a next-generation version of Regeneron's proprietary VelocImmune® technology and created using the company's VelociBi™ platform.

There are six Regeneron investigational bispecific antibodies currently in ongoing clinical trials for multiple blood cancers and solid tumors. These bispecifics fall into three categories:

  • CD3 bispecifics are designed to bridge T-cells and tumor cells. At the tumor site, they activate T-cells via their CD3 receptors and promote T-cell killing of the cancer cells. Investigational candidates include:
  • CD28 costimulatory bispecifics are also designed to bridge T-cells and tumor cells. At the tumor site, they costimulate T-cells via their CD28 receptors and may synergize with PD-1 inhibitors and/or CD3 bispecifics. Investigational candidates include:
  • Tumor-targeted bispecifics are designed to target proteins only on the cancer cell. In this way, they may affect various signaling pathways to hamper the cancer cells' ability to survive and proliferate. Investigational candidates include:

Regulatory Status of Programs
REGN1979, REGN5458, REGN5459, REGN4018, REGN5678, REGN5093, pozelimab and Libtayo are currently under clinical development for the diseases noted in this press release, and their safety and efficacy have not been evaluated by any regulatory authority for these diseases. As part of a global collaboration agreement, Regeneron and Sanofi are jointly developing Libtayo, as well as Regeneron's BCMAxCD3 and MUC16xCD3 bispecific programs.

Libtayo is approved in the U.S. for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation, and in other countries for similar indications. In the U.S., the generic name for Libtayo is cemiplimab-rwlc, with rwlc as the suffix designated in accordance with Nonproprietary Naming of Biological Products Guidance for Industry issued by the U.S. Food and Drug Administration.

About Regeneron Pharmaceuticals, Inc.
Regeneron (REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, pain and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune®, which uses a unique genetically-humanized mouse to produce optimized fully-human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Regeneron Forward-Looking Statements and Use of Digital Media
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron's products, product candidates, and research and clinical programs now underway or planned, including without limitation REGN1979 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma and other potential indications, as well as REGN5458 (BCMAxCD3 bispecific antibody being investigated in multiple myeloma) and pozelimab (C5 antibody), and Regeneron's earlier-stage product candidates (such as Regeneron's other bispecific antibodies and costimulatory bispecific antibody discussed in this press release (as a monotherapy or in combination with Libtayo® (cemiplimab), as applicable)); unforeseen safety issues resulting from the administration of products and product candidates in patients, including serious complications or side effects in connection with the use of Regeneron's product candidates (such as REGN1979, REGN5458, and pozelimab) in clinical trials; the extent to which the results from the research and development programs conducted by Regeneron or its collaborators may be replicated in other studies and lead to therapeutic applications; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates and new indications for marketed products; ongoing regulatory obligations and oversight impacting Regeneron's marketed products, research and clinical programs, and business, including those relating to patient privacy; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's products and product candidates; competing drugs and product candidates that may be superior to Regeneron's products and product candidates; uncertainty of market acceptance and commercial success of Regeneron's products and product candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary) on the commercial success of Regeneron's products and product candidates; the ability of Regeneron to manufacture and manage supply chains for multiple products and product candidates; the ability of Regeneron's collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's products and product candidates; the availability and extent of reimbursement of the Company's products from third-party payers, including private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payers and new policies and procedures adopted by such payers; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi, Bayer, and Teva Pharmaceutical Industries Ltd. (or their respective affiliated companies, as applicable), to be cancelled or terminated without any further product success; and risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to Dupixent® (dupilumab) and Praluent® (alirocumab)), other litigation and other proceedings and government investigations relating to the Company and/or its operations, the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron's business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron's filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the fiscal year ended December 31, 2018 and its Form 10-Q for the quarterly period ended September 30, 2019. Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update publicly any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (http://newsroom.regeneron.com) and its Twitter feed (http://twitter.com/regeneron).

Contacts:

Media Relations
Daren Kwok
Tel: +1 (914) 847-1328
Daren.Kwok@regeneron.com

Investor Relations
Justin Holko
Tel: +1 (914) 847-7786
Justin.Holko@regeneron.com

Cision

View original content:http://www.prnewswire.com/news-releases/regeneron-to-report-results-from-cd20xcd3-and-bcmaxcd3-bispecifics-and-c5-antibody-programs-at-ash-annual-meeting-300952821.html

  • Robert Wares Is The Non-Executive Director of Osisko Mining Inc. (TSE:OSK) And They Just Spent CA$340k On Shares
    Business
    Simply Wall St.

    Robert Wares Is The Non-Executive Director of Osisko Mining Inc. (TSE:OSK) And They Just Spent CA$340k On Shares

    Investors who take an interest in Osisko Mining Inc. (TSE:OSK) should definitely note that the Non-Executive Director, Robert Wares, recently paid CA$3.40 per share to buy CA$340k worth of the stock. In the last twelve months, the biggest single purchase by an insider was when Director Jose Vizquerra-Benavides bought CA$2.0m worth of shares at a price of CA$3.15 per share. In the last twelve months insiders purchased 1.49m shares for CA$4.6m.

  • Did Hedge Funds Drop The Ball On Intra-Cellular Therapies Inc (ITCI) ?
    Business
    Insider Monkey

    Did Hedge Funds Drop The Ball On Intra-Cellular Therapies Inc (ITCI) ?

    With this in mind, as the current round of 13F filings has just ended, let's examine the smart money sentiment towards Intra-Cellular Therapies Inc (NASDAQ:ITCI). Hedge fund interest in Intra-Cellular Therapies Inc (NASDAQ:ITCI) shares was flat at the end of last quarter. At the end of this article we will also compare ITCI to other stocks including New Frontier Corporation (NYSE:NFC), Chuy's Holdings Inc (NASDAQ:CHUY), and IRSA Propiedades Comerciales S.A. (NASDAQ:IRCP) to get a better sense of its popularity.

  • Hedge Funds Have Never Been More Bullish On Coca-Cola FEMSA, S.A.B. de C.V.  (KOF)
    Business
    Insider Monkey

    Hedge Funds Have Never Been More Bullish On Coca-Cola FEMSA, S.A.B. de C.V. (KOF)

    It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Conversely, hedge funds' top 20 large-cap stock picks generated a return of 37.4% during the same 11-month period, with the majority of these stock picks outperforming the broader market benchmark.

  • Here’s the formula for paying no federal income taxes on $100,000 a year
    Business
    MarketWatch

    Here’s the formula for paying no federal income taxes on $100,000 a year

    The question of how much can we earn without paying federal income taxes is relatively easy to answer for most people. The standard deduction for a married couple is $24,400 in 2019 (if both are under 65 years old), and the top of the 0% capital-gains tax bracket is $78,750. With our daughter, we also qualify for the child tax credit ($2,000), so we could actually generate another $13,333 per year in dividends or capital gains, taxed at 15%.

  • Is Affimed NV (AFMD) Going to Burn These Hedge Funds?
    Business
    Insider Monkey

    Is Affimed NV (AFMD) Going to Burn These Hedge Funds?

    After several tireless days we have finished crunching the numbers from nearly 750 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms' equity portfolios as of September 30th. The results of that effort will be put on display in this article, as we share valuable insight into the smart money sentiment towards Affimed NV (NASDAQ:AFMD). Is Affimed NV (NASDAQ:AFMD) the right pick for your portfolio?

  • Should You Avoid Ituran Location and Control Ltd. (ITRN)?
    Business
    Insider Monkey

    Should You Avoid Ituran Location and Control Ltd. (ITRN)?

    Before putting in our own effort and resources into finding a good investment, we can quickly utilize hedge fund expertise to give us a quick glimpse of whether that stock could make for a good addition to our portfolios. This year hedge funds' top 20 stock picks outperformed the S&P 500 Index by 9.9 percentage points through the end of November. Thus, we can see that the tireless research and efforts of hedge funds to identify winning stocks can work to our advantage when we know how to use the data.

  • Hedge Funds Are Dumping ImmunoGen, Inc. (IMGN)
    Business
    Insider Monkey

    Hedge Funds Are Dumping ImmunoGen, Inc. (IMGN)

    That's why we weren't surprised when hedge funds' top 20 large-cap stock picks generated a return of 37.4% through the end of November and outperformed the broader market benchmark by 9.9 percentage points.This is why following the smart money sentiment is a useful tool at identifying the next stock to invest in. ImmunoGen, Inc. NASDAQ:IMGN) investors should pay attention to a decrease in enthusiasm from smart money in recent months.

  • Futures see gains on US-China trade agreement, Nasdaq sees upside
    Business
    Trading Central

    Futures see gains on US-China trade agreement, Nasdaq sees upside

    Before the bell, US futures are soaring after the US and China reached a trade agreement. Meanwhile, the Nasdaq is in focus.

  • Hedge Funds Are Dumping FutureFuel Corp. (FF)
    Business
    Insider Monkey

    Hedge Funds Are Dumping FutureFuel Corp. (FF)

    With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the second quarter. One of these stocks was FutureFuel Corp. NYSE:FF).

  • Hedge Funds Are Dumping Altair Engineering Inc. (ALTR)
    Business
    Insider Monkey

    Hedge Funds Are Dumping Altair Engineering Inc. (ALTR)

    What does smart money think about Altair Engineering Inc. NASDAQ:ALTR)? At the end of the third quarter, a total of 10 of the hedge funds tracked by Insider Monkey held long positions in this stock, a change of -29% from the second quarter of 2019.

  • Billionaire George Soros Snaps Up These 3 High-Yield Dividend Stocks
    Business
    TipRanks

    Billionaire George Soros Snaps Up These 3 High-Yield Dividend Stocks

    To watch Boyd's track record, click here) BP shares have received three recent Buy ratings, giving the stock a unanimous 'Strong Buy' from the analyst consensus. The average price target stands tall at $51.33 -- indicating a robust upside potential of 39%. See BP stock analysis on TipRanks) BP wasn't the only energy industry company that Soros was interested in.

  • Is Cronos Group Inc. (CRON) A Good Stock To Buy?
    Business
    Insider Monkey

    Is Cronos Group Inc. (CRON) A Good Stock To Buy?

    A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. Cronos Group Inc. (NASDAQ:CRON) has experienced an increase in support from the world's most elite money managers in recent months. Video: Click the image to watch our video about the top 5 most popular hedge fund stocks.

  • Is Corporacion America Airports SA (CAAP) A Good Stock To Buy?
    Business
    Insider Monkey

    Is Corporacion America Airports SA (CAAP) A Good Stock To Buy?

    The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing more than 750 13F filings submitted by hedge funds and prominent investors. Overall, hedge fund sentiment was unchanged.

  • Is It Worth Buying Costco Wholesale Corporation (NASDAQ:COST) For Its 0.9% Dividend Yield?
    Business
    Simply Wall St.

    Is It Worth Buying Costco Wholesale Corporation (NASDAQ:COST) For Its 0.9% Dividend Yield?

    Of the free cash flow it generated last year, Costco Wholesale paid out 31% as dividends, suggesting the dividend is affordable. It's encouraging to see that the dividend is covered by both profit and cash flow. This generally suggests the dividend is sustainable, as long as earnings don't drop precipitously.

  • Hedge Funds Have Never Been More Bullish On New York Mortgage Trust, Inc. (NYMT)
    Business
    Insider Monkey

    Hedge Funds Have Never Been More Bullish On New York Mortgage Trust, Inc. (NYMT)

    Hedge funds and institutional investors tracked by Insider Monkey usually invest a disproportionate amount of their portfolios in smaller cap stocks. In this article, we will take a closer look at hedge fund sentiment towards New York Mortgage Trust, Inc. (NASDAQ:NYMT). Overall, hedge fund sentiment was unchanged.

  • Tips for end of year retirement planning
    Business
    Yahoo Finance Video

    Tips for end of year retirement planning

    As the year closes out, it's a good time to take stock of where your finances stand and start preparing for your financial future. Bill Smith, managing director for CBIZ MHM's National Tax Office, joined The Final Round to discuss.

  • Boeing loses battle to develop long-haul plane
    Business
    American City Business Journals

    Boeing loses battle to develop long-haul plane

    The Boeing Co. has lost out to rival Airbus in the bid to develop an aircraft that Australian flagship carrier Qantas aims to introduce on ultra-long-haul flights. The plane could be used on the Chicago-to-Brisbane route that Qantas will start flying on April 15. Qantas CEO Alan Joyce said of the carrier's choice of the Airbus model aircraft: “Airbus gives us the best possible combination of commercial terms, fuel efficiency, operating cost and customer experience.” Qantas' decision to go with a version of the Airbus A350-1000 comes after Boeing (NYSE: BA) has been in the public spotlight for months as multiple agencies have investigated the development of the troubled Boeing 737 MAX.

  • Bristol-Myers wins $752 million in U.S. patent case against Gilead
    Business
    Reuters

    Bristol-Myers wins $752 million in U.S. patent case against Gilead

    Bristol-Myers Squibb Co on Friday said it won a $752 million jury verdict against Gilead Sciences Inc in a U.S. patent dispute relating to technology for treating cancer. A jury in Los Angeles awarded the damages after finding that Yescarta, a treatment sold by Gilead's Kite Pharma unit, infringed on a patent exclusively licensed by Bristol-Myers' Juno Therapeutics division. The patent at issue in the lawsuit, which Juno licenses from the Memorial Sloan Kettering Cancer Center in New York, relates to CAR T-cell immunotherapy for cancer.

  • A Close Look At Verizon Communications Inc.’s (NYSE:VZ) 13% ROCE
    Business
    Simply Wall St.

    A Close Look At Verizon Communications Inc.’s (NYSE:VZ) 13% ROCE

    Today we'll evaluate Verizon Communications Inc. (NYSE:VZ) to determine whether it could have potential as an investment idea. Specifically, we're going to calculate its Return On Capital Employed (ROCE), in the hopes of getting some insight into the business. First up, we'll look at what ROCE is and how we calculate it.

  • Hedge Funds Have Never Been More Bullish On Agile Therapeutics Inc (AGRX)
    Business
    Insider Monkey

    Hedge Funds Have Never Been More Bullish On Agile Therapeutics Inc (AGRX)

    That's why we weren't surprised when hedge funds' top 20 large-cap stock picks generated a return of 37.6% in 2019 (through the end of November) and outperformed the broader market benchmark by 9.9 percentage points.This is why following the smart money sentiment is a useful tool at identifying the next stock to invest in. Agile Therapeutics Inc (NASDAQ:AGRX) was in 10 hedge funds' portfolios at the end of September. AGRX investors should be aware of an increase in hedge fund interest recently.

  • Top Undervalued Companies Owned by Activist Investors, Part 1
    Business
    GuruFocus.com

    Top Undervalued Companies Owned by Activist Investors, Part 1

    ADS 30-Year Financial Data The intrinsic value of ADS Peter Lynch Chart of ADS Since there is a good deal of overlap in activist investing and value investing, the following companies may be worth keeping an eye on, since they are owned by activist investors and have many qualities that make them attractive from a value investing standpoint. Jeff Ubben and Alliance Data Systems Jeff Ubben (Trades, Portfolio) is the co-founder, CEO and chief investment officer of ValueAct Capital. The firm's activist investing strategy focuses on investing for the long term in high-quality companies in which they are able to establish communicative relationships with management.

  • Is Frontier Communications Corporation (FTR) Going to Burn These Hedge Funds?
    Business
    Insider Monkey

    Is Frontier Communications Corporation (FTR) Going to Burn These Hedge Funds?

    The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. In this article, we analyze how these elite funds and prominent investors traded Frontier Communications Corporation (NASDAQ:FTR) based on those filings. Frontier Communications Corporation (NASDAQ:FTR) shares haven't seen a lot of action during the third quarter.

  • Did Hedge Funds Drop The Ball On Ascena Retail Group Inc (ASNA)?
    Business
    Insider Monkey

    Did Hedge Funds Drop The Ball On Ascena Retail Group Inc (ASNA)?

    That's why we weren't surprised when hedge funds' top 20 large-cap stock picks generated a return of 37.6% in 2019 (through the end of November) and outperformed the broader market benchmark by 9.9 percentage points.This is why following the smart money sentiment is a useful tool at identifying the next stock to invest in. Ascena Retail Group Inc (NASDAQ:ASNA) shares haven't seen a lot of action during the third quarter. Overall, hedge fund sentiment was unchanged.

  • Taylor Swift Calls Out Soros Family in Fight With Private Equity
    News
    Bloomberg

    Taylor Swift Calls Out Soros Family in Fight With Private Equity

    Taylor Swift renewed her criticism of private equity, calling out the Carlyle Group and the Soros family for helping her nemesis Scooter Braun purchase the rights to her old music. In a speech at a Billboard Women in Music event Thursday night, she called the increasing presence of private equity in the music industry a “potentially harmful force,” decrying that the firms are unregulated and “buying up our music as if it is real estate. Swift took direct shots at Soros, Carlyle and the sports and media-focused investment firm 23 Capital for helping music manager Braun's Ithaca Holdings purchase of her old catalog.

  • 3D Systems Corporation (DDD): Hedge Funds Are Snapping Up
    Business
    Insider Monkey

    3D Systems Corporation (DDD): Hedge Funds Are Snapping Up

    Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Hedge funds underperform because they are hedged.